194 related articles for article (PubMed ID: 35526322)
1. Acetylshikonin exerts anti-tumor effects on non-small cell lung cancer through dual inhibition of STAT3 and EGFR.
Tang Y; Wang Y; Wang X; Zhao Z; Cai H; Xie M; Jiang X; Zhang L; Cheng J; Yang L; Wang L; Zhao C; Huang X
Phytomedicine; 2022 Jul; 101():154109. PubMed ID: 35526322
[TBL] [Abstract][Full Text] [Related]
2. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
4. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
5. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. Suppression of EGFR/STAT3 activity by lupeol contributes to the induction of the apoptosis of human non‑small cell lung cancer cells.
Min TR; Park HJ; Ha KT; Chi GY; Choi YH; Park SH
Int J Oncol; 2019 Jul; 55(1):320-330. PubMed ID: 31115519
[TBL] [Abstract][Full Text] [Related]
8. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer.
Xie C; Zhou X; Liang C; Li X; Ge M; Chen Y; Yin J; Zhu J; Zhong C
J Exp Clin Cancer Res; 2021 Aug; 40(1):266. PubMed ID: 34429133
[TBL] [Abstract][Full Text] [Related]
9. STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer.
Njatcha C; Farooqui M; Kornberg A; Johnson DE; Grandis JR; Siegfried JM
Mol Cancer Ther; 2018 Sep; 17(9):1917-1926. PubMed ID: 29891486
[TBL] [Abstract][Full Text] [Related]
10. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Chaib I; Karachaliou N; Pilotto S; Codony Servat J; Cai X; Li X; Drozdowskyj A; Servat CC; Yang J; Hu C; Cardona AF; Vivanco GL; Vergnenegre A; Sanchez JM; Provencio M; de Marinis F; Passaro A; Carcereny E; Reguart N; Campelo CG; Teixido C; Sperduti I; Rodriguez S; Lazzari C; Verlicchi A; de Aguirre I; Queralt C; Wei J; Estrada R; Puig de la Bellacasa R; Ramirez JL; Jacobson K; Ditzel HJ; Santarpia M; Viteri S; Molina MA; Zhou C; Cao P; Ma PC; Bivona TG; Rosell R
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28376152
[TBL] [Abstract][Full Text] [Related]
11. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
[TBL] [Abstract][Full Text] [Related]
12. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
[TBL] [Abstract][Full Text] [Related]
13. Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway.
Zhou J; Liu Y; Chen J; Xiong N; Yi D
Drug Dev Res; 2023 May; 84(3):592-610. PubMed ID: 36852868
[TBL] [Abstract][Full Text] [Related]
14. Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR
Wang G; Zhao J; Zhang M; Wang Q; Chen B; Hou Y; Lu K
Int J Nanomedicine; 2019; 14():4503-4515. PubMed ID: 31417255
[No Abstract] [Full Text] [Related]
15. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
16. Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
Zhang Y; Zhang Y; Niu W; Ge X; Li X; Fan F; Li S; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 46(10):1045-1053. PubMed ID: 34911833
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
Jeong MS; Lee KW; Choi YJ; Kim YG; Hwang HH; Lee SY; Jung SE; Park SA; Lee JH; Joo YJ; Cho SG; Ko SG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445110
[TBL] [Abstract][Full Text] [Related]
18. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and Survivin expression to potentiate ABT-263-induced apoptosis in Non-small Cell Lung Cancer cells harboring EGFR or RAS mutation.
Yan X; Li P; Zhan Y; Qi M; Liu J; An Z; Yang W; Xiao H; Wu H; Qi Y; Shao H
Biochem Pharmacol; 2018 Apr; 150():72-85. PubMed ID: 29360439
[TBL] [Abstract][Full Text] [Related]
19. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
Lee HJ; Min HY; Yong YS; Ann J; Nguyen CT; La MT; Hyun SY; Le HT; Kim H; Kwon H; Nam G; Park HJ; Lee J; Lee HY
Theranostics; 2022; 12(1):105-125. PubMed ID: 34987637
[No Abstract] [Full Text] [Related]
20. Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells.
Yin ZJ; Jin FG; Liu TG; Fu EQ; Xie YH; Sun RL
J Surg Res; 2011 Dec; 171(2):675-83. PubMed ID: 20605584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
